US Intel Report Reveals No Incident Occurred at Wuhan Lab That Could Have Caused Pandemic, along with some observations and sarcasm

June 25, 2023June 26, 2023 Ms. Cat

*But anonymous sources, at the State Department, told me that ‘patient zero’ had COVID-19! 🙄

Cleared by Congress, legislation later signed by US President Joe Biden in March ordered the Director of National Intelligence (DNI) to declassify information regarding the potential origins of SARS-CoV-2, the virus that causes COVID-19. The measure forced the DNI to declassify its report within 90 days.
US Intel Report Reveals No Incident Occurred at Wuhan Lab That Could Have Caused Pandemic

H/T: Unorthodox Truth

*Some observations: WCWP does not seem to prove that Ben Hu was ‘patient zero’. They link to a Daily Caller article, whose source is David Asher, who served in Trump’s State Department. He also happens to be a former Adjunct Senior Fellow at the ‘liberal’ hawkish think tank, Center for a New American Security. He’s currently a senior fellow at Hudson Institute and on the board of advisors of FDD’s Center on Economic and Financial Power (more neocon/hawkish think tanks). They also quote former FDA Commissioner, Dr. Scott Gottlieb, whom happens to be a Senior Fellow at the American Enterprise Institute (neocon think tank) and on the boards of directors for Illumina, Inc and Pfizer (Big Pharma). See a pattern, here?!

Hu and two of his WIV colleagues were thrown into the furious COVID-19 origin debate on 13 June when an online newsletter called Public said the three scientists developed COVID-19 in November 2019. That was prior to the outbreak becoming public when a cluster of cases at the end of December 2019 surfaced in people linked to a Wuhan marketplace. Public’s report was quickly embraced by a camp that argues COVID-19 came from a virus stored, and possibly manipulated, at WIV, rather than from infected animal hosts, perhaps being sold at the Wuhan market. A Wall Street Journal (WSJ) article on 20 June that said it had “confirmed” the allegations against the three, without referring to any public evidence or named sources with direct knowledge, fueled the flames even more. Social media and other publications spread the charges—and the scientists’ names.

COVID Infection Provides Immunity Equal to Vaccination: Study

February 17, 2023February 17, 2023 Ms. Cat

COVID Infection Provides Immunity Equal to Vaccination: Study

Feb. 17, 2023 — The natural immunity provided by a COVID infection protects a person against severe illness on a par with two doses of mRNA vaccine, a new study says.

…

But protection against the BA.1 subvariant of Omicron was not as high – 36% at 10 months after infection, says the research team from the Institute for Health Metrics and Evaluation at the University of Washington.

The researchers examined 65 studies from 19 countries through Sept. 31, 2022. They did not study data about infection from Omicron XBB and its sub-lineages. People who had immunity from both infection and vaccination, known as hybrid immunity, were not studied.

It’s Worse Than I Thought: The Myth of Jeffrey Zients

January 27, 2023January 27, 2023 Ms. Cat

There is no reason to trust a longtime corporate stooge to serve as President Biden’s chief of staff.
The Myth of Jeffrey Zients

Related (Archived Links):

From FDA to MHRA: are drug regulators for hire?

January 25, 2023January 25, 2023 Ms. Cat

Patients and doctors expect drug regulators to provide an unbiased, rigorous assessment of investigational medicines before they hit the market. But do they have sufficient independence from the companies they are meant to regulate? Maryanne Demasi investigates
From FDA to MHRA: are drug regulators for hire?

Why India did not allow Pfizer’s Covid-19 vaccine

January 25, 2023January 25, 2023 Ms. Cat

Why India did not allow Pfizer’s Covid-19 vaccine

In Latin America pharmaceutical bullying went a notch higher. In addition to legal indemnity, Pfizer demanded protection against their own negligence and mistakes. Argentina amended its vaccine law, three times, yet Pfizer was not happy. Pfizer wanted Argentina’s bank reserves and military bases as “guarantees”.

In the era of neo-colonialism, Pharma industry was the new East India Company.

…

Despite such pressure, India did not succumb. Eventually, Pfizer withdrew its application in 2021 We continued our vaccine programme with drugs that complied with our legal requirements.

Twitter censored tweets after pressure from Pfizer director

January 9, 2023January 9, 2023 Ms. Cat

The Pfizer board member directly contacted Twitter and expressed concerns about a tweet “going viral.”
Twitter censored tweets after pressure from Pfizer director

No Accountability for Pfizer as Bourla Ignores EU Covid Committee Hearings

October 3, 2022October 3, 2022 Ms. Cat

Because when your this ‘special’ (big, big pharma) accountability isn’t in your vocabulary. Privilege has it’s benefits.

Pfizer CEO backs out of EU COVID committee hearing
No Accountability for Pfizer as Bourla Ignores EU Covid Committee Hearings

New COVID Booster Approved From Final Study of Mice, Not Humans, But Using Only Animal Data Is a Needless Gamble

September 10, 2022September 10, 2022 Ms. Cat

VERIFY: New COVID booster approved from final study of mice, not humans

According to documents on the CDC website, human tests of Moderna’s version of the new booster are still “ongoing.” Right now, there is only final evidence from “8-10 mice” per group.”

The FDA’s website shows for Pfizer the agency also relayed on the final study evidence from “8 mice.” But human trials are also ongoing. So far, the new boosters “showed a similar local reaction and systemic event profile.” That means side effects appear to be about the same including “mild to moderate injection site pain, fatigue, and muscle pain.”

…

“To advance the Omicron BA.4/BA.5 bivalent vaccine as rapidly as possible, regulators, including the FDA, WHO and EMA, have advised that our submissions be based on safety and immunogenicity data generated in adults with an Omicron BA.1 bivalent vaccine and supported by BA.4/BA.5 bivalent pre-clinical data and BA.4/BA.5 bivalent quality and manufacturing data. These packages follow a similar model to that provided to public health officials who evaluate seasonal flu vaccines each year. Moving forward, this approach may help address the pressing need for vaccines that provide a high level of protection against current and emerging variants of concern so that we can remain vigilant against this evolving virus. The FDA has authorized our Omicron BA.4/BA.5 bivalent vaccine based on clinical data generated in adults with an Omicron BA.1 bivalent vaccine, pre-clinical data with a BA.4/BA.5 bivalent vaccine and BA.4/BA.5 bivalent quality and manufacturing data. Pre-clinical data showed a booster dose of Pfizer and BioNTech’s Omicron BA.4/BA.5- bivalent vaccine generated a strong neutralizing antibody response against Omicron BA.1, BA.2 and BA.4/BA.5 variants, as well as the original wild-type strain. A clinical study investigating the safety, tolerability and immunogenicity of the Omicron BA.4/BA.5 bivalent vaccine in individuals 12 years of age and older is ongoing. Data will be shared with regulators when available. We are facing a virus with an exceptionally high mutation rate, which the nimble mRNA platform is well situated to address. Only the mRNA sequence requires updating to match emerging strains, and utilizing a bivalent vaccine aims to provide broader coverage against known and future COVID-19 variants of concern.”

Related:

Pfizer’s anti-COVID pill Paxlovid shows no benefit for younger adults

August 28, 2022August 28, 2022 Ms. Cat

Pfizer’s anti-COVID pill Paxlovid shows no benefit for younger adults

The report’s authors found that Pfizer’s antiviral medication Paxlovid offered little to no benefit for younger adults. However, it did reduce the risk of hospitalization for high-risk seniors. Notably, supplementary material from the original study of Paxlovid in high-risk non-hospitalized adults with COVID-19 during the Delta wave had demonstrated benefits in those younger than 65, albeit the difference compared to the placebo was much less than in those 65 and older.

…

Among those over 65, there was a 73 percent decrease in the hospitalization rate and a 79 percent reduction in the risk of death. However, patients between the ages of 40 and 65 saw no benefit in taking the antiviral medication in either category, regardless of previous immunity status.

…

Another critical study from Hong Kong published in Lancet Infectious Diseases on the same day as the Israeli study but which went unmentioned in the press offered further evidence of Paxlovid’s limited therapeutic role. The authors reviewed their clinical experience with Paxlovid and Lagevrio, Merck’s antiviral pill, Molnupiravir, in hospitalized patients. They compared them to hospitalized patients who did not receive those medications during the horrific wave of infections that slammed into the semi-autonomous region in February and March.

…

The mortality risk reduction for Lagevrio was 52 percent, and for Paxlovid it was 66 percent. Those receiving antivirals had a lower risk of their disease progressing, but the drugs did not significantly impact their need for mechanical ventilation or ICU admission. The patients in the study averaged in age from mid-70s to early 80s.

…

Given the results of these studies, it bears mentioning that the Centers for Disease Control and Prevention (CDC) has recently estimated that approximately 95 percent of Americans aged 16 and older have some level of immunity against COVID-19.